{
  "abstract": "Objective: Moxifloxacin, a widely used fluoroquinolone, has been associated with oxidative stress and tissue injury. Resveratrol may attenuate oxidative damage. This study investigated the effects of resveratrol co-administration on oxidative and apoptotic biomarkers in rats exposed to moxifloxacin.\n\nMethods: Twenty-four male Wistar albino rats were randomly assigned to three groups (n = 8 per group): (a) control; (b) moxifloxacin; and (c) moxifloxacin + resveratrol groups. Moxifloxacin was administered intraperitoneally at 50 mg/kg/day during the final 7 days of a 28-day experimental period, whereas resveratrol was administered at 40 mg/kg/day for 28 days. Levels of superoxide dismutase, malondialdehyde, and caspase-3 as well as total antioxidant status and total oxidant status were assessed in the serum, brain, kidney, and liver tissues.\n\nResults: Serum total antioxidant status significantly decreased in the moxifloxacin group compared with that in the control group (2.639 ± 0.169 vs. 3.531 ± 0.176 mmol Trolox equivalent/L, p = 0.007). Co-administration of moxifloxacin and resveratrol significantly increased serum total antioxidant status compared with administration of moxifloxacin alone (3.380 ± 0.190 vs. 2.639 ± 0.169 mmol Trolox equivalent/L, p = 0.018), whereas no significant difference was observed in the control group (p = 0.557). Kidney total oxidant status was significantly higher in the moxifloxacin group than in the control (p = 0.008) and moxifloxacin + resveratrol (p = 0.002) groups. Liver superoxide dismutase levels were significantly lower in the moxifloxacin group than in the control (p < 0.001) and moxifloxacin + resveratrol (p = 0.001) groups. Kidney caspase-3 levels were significantly increased in the moxifloxacin group compared with those in the control group (p < 0.001), whereas co-administration of moxifloxacin and resveratrol partially attenuated this alteration. Additionally, moxifloxacin increased the levels of malondialdehyde in the kidney, liver, and brain tissues, with attenuation following resveratrol co-administration.\n\nConclusions: Resveratrol co-administration attenuated several moxifloxacin-associated oxidative and apoptotic alterations, particularly in the kidney and liver tissues. However, the absence of a resveratrol-only group and the preconditioning design limit the interpretation of its independent effects and clinical applicability. Further pharmacokinetic, mechanistic, and clinical studies are required.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Chest Disease, Private Medicana Hospital, Türkiye",
    "Department of Physiology, Faculty of Medicine, Uludağ University, Türkiye"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Gülfem Yıldırım",
      "orcid": "0000-0001-5300-6607"
    },
    {
      "affs": [
        1
      ],
      "name": "Ayşen Çakır"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/49jhssd56b789.bib",
  "cited_by": 0,
  "doi": "10.1177/03000605261488102",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13724877/",
  "id": "49jhssd56b789",
  "issns": [
    "0300-0605",
    "1473-2300"
  ],
  "landing_url": "https://doi.org/10.1177/03000605261488102",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Preclinical Study"
    ],
    [
      "openalex",
      "3004|Drug-Induced Hepatotoxicity and Protection"
    ]
  ],
  "openalex": "W7213289060",
  "pdf_url": null,
  "pmcid": "PMC13724877",
  "pmid": "42745652",
  "published": "2026-09-16",
  "publisher": "SAGE Publications",
  "ris": "https://research.draconitic.com/paper/49jhssd56b789.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T12:23:22Z",
      "native_id": "PMC13724877",
      "source": "pmc",
      "url": "https://doi.org/10.1177/03000605261488102"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:3004|Drug-Induced Hepatotoxicity and Protection",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Resveratrol attenuates moxifloxacin-induced oxidative damage in the liver, kidneys, brain, and serum of Wistar rats",
  "title_text": "Resveratrol attenuates moxifloxacin-induced oxidative damage in the liver, kidneys, brain, and serum of Wistar rats",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T12:21:15Z",
  "url": "https://research.draconitic.com/paper/49jhssd56b789",
  "venue": "The Journal of International Medical Research",
  "versions": []
}